Accordingly, CD39+ tumor-infiltrating Tregs may produce IL-17, in contrast to CD39- tumor-Tregs, in colon cancer patients [51], supporting the hypothesis that CD39+ IL-17-producing cells play a determining role in cancer. This evidence concerns the gene ENTPD1 and colonic neoplasm.